GNBT,
Generex Biotechnology Has Strong Presence at Annual Canadian Diabetes Association Conference
Thursday October 19, 10:25 am ET
TORONTO--(MARKET WIRE)--Oct 19, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, will make a podium presentation today at the 2006 Canadian Diabetes Association (CDA) Professional Conference and Annual Meetings in Toronto, Canada. The presentation, to be made by Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs, relates to Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product, and is of a paper entitled 3-Month Interim Results (6-Month Study) on Safety and Efficacy of an Oral Insulin (Generex Oral-lyn(TM)) Administered at Lunchtime in Juvenile Type-1 Diabetes Mellitus Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin. The paper was co-authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR in Quito, Ecuador.
ADVERTISEMENT
In addition, the following Generex-sponsored studies are the subject of poster presentations at the CDA Professional Conference: The first poster, entitled Generex Metformin Gum: An Alternative Method for Delivery of Biguanides, was authored by Drs. Jaime Guevara-Aguirre, David Saldarreaga, Marco Guevara-Aguirre, and Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito, Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President - Medical Affairs. The second poster, entitled Ii-Key/Insulin MHC Class-II Antigenic Epitope Peptides in Type 1 Diabetes was authored by Professor Paolo Pozzilli and Dr. Marta Vadacca, both of the Department of Endocrinology and Diabetes at University Campus Bio-Medico, together with Robert E. Humphreys, Nikoletta L. Kallinteris, Luciana Valente, and Giuditta Valorani. |
